|s-1360 go on or failed?
Nov 2, 2003
s-1360 a winner or failed?
Integrase Inhibitor: S-1360 S-1360 is a diketo acid being developed by Shinogi Pharmaceuticals and GlaxoSmithKline. Preliminary data from early preclinical and clinical studies were reported at the 2002 Retrovirus conference and at the XIV International AIDS Conference in Barcelona. According to in vitro data reported at the Seattle meeting, S-1360 is synergistic with all of the available antiretrovirals and has potency that is on a par with lamivudine. In animal models, S-1360 was found to be 70 to 80 bio-available and had a half-life ranging from one to two hours. As for clinical data, 18 HIV-negative study volunteers received single doses of S-1360. In all 18 people, the plasma half-life ranged from 7.7 to 16 hours, meaning that once-daily dosing is possible. Phase I and II studies of S-1360, in HIV-infected people, are under way.
| Response from Dr. Pierone
Unfortunately it failed and is no longer being developed.
Get Email Notifications When This Forum Updates or Subscribe With RSS
- What Pills Can You Take To Get Rid Of Bacterial Vaginosis Or A Yeast Infection?
- What Percentage Of People With Hpv Get Genital Warts?
- What Causes Hpv To Reoccur?
- What Are The Chances Of Getting Herpes Or Warts From A Safe Exposure With A Prostitute?
- What Are My Chances Of Catching Chlamydia?
- Is Ti Common To Get A Uti Before Herpes Outbreak?
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.